Yes the reps have been to my clinic twice already. They have received a positive reception with my partners. Its possible I may start prescribing this drug as early as this coming week.
27 Dec 2015, 09:24 PM
Given your experience as a doctor, what type of patient would you give Veltassa to? Mild, moderate, or severe hyperkylemia? What percent of your patients would be prescribed it? I feel 5% penetration is low, but what is more realistic?
01 Jan 2016, 12:39 PM
So far this week I have prescribed it to three patients. All had mild-mod hyperkalemia ie between 5.5 and 6.5. I will use this drug mostly in patients with chronic kidney disease, They have a difficult time excreting the potassium, and it is hard to adhere to low potassium diet especially when foods that are generally considered healthy like tomatoes, fruits and vegetables are restricted. The specialty pharmacy handling Veltassa has been very efficient, and my first patient got his ten day supple in the mail within 3-4 days. So far, I am impressed with the roll out.
Shire ($SHPG) has offered up a new bid for elusive target Baxalta ($BXLT) that's more or less what the Illinois drugmaker has been looking for, reports say. But that doesn't mean Baxalta isn't exploring its other options.
The Baxter ($BAX) spinoff is checking out alternatives to its longtime suitor, the Financial Times reports, contacting other companies that may be interested in joining hands. While it hasn't fielded any other offers, it's trying to make sure it gets the best possible price, the newspaper notes.
The way analysts see it, potential partners could include Sanofi ($SNY) or AbbVie ($ABBV), which last year agreed to merge with Shire itself before new, stricter rules on tax inversions forced it to pull the plug. But Shire, based in tax-advantaged Ireland, has an leg up in its pursuit that could make it a tough opponent.
Baxalta reportedly likes its fallback option, too. Shire, once hesitant to fund its bid with cash for fear of upsetting the tax benefits conferred by Baxalta's July spinoff, now sees a way to include cash in its bid without triggering a hefty tax penalty.
Shire CEO Flemming Ornskov
And that cash has propelled talks between the two companies to the next level, Reuters says, which could make a buyout agreement a reality within the coming weeks. No matter what the terms, expect the deal to outvalue the $30 billion Baxalta shot down as a "lowball" offer this summer, one source told the news service.
If Shire can pull off a pact, no one will be happier than CEO Flemming Ornskov. With dreams of $20 billion in combined sales by 2020, the Shire skipper has been doggedly pursuing Baxalta for more than 6 months, Reuters reported in November.
- read the FT story (sub. req.)
- get more from Reuters
Intercept +9.5% Premarket @$152.99; 'This is Money' Reported Monday that Shire Could be a Bidder for the Co
Relypsa is interesting as a buy out, even after it has gone up. Unfortunately all my shares had covered calls. Black box warning means nothing towards drug's use. I don't think anything serious is occurring but if it settles down people might want to check it out as takeout is 40 and maybe as high as 70. What the companies said:
I want to emphasize at this point that this is just a rumor, as a representative from Relypsa declined to comment on the situation. Merck also declined to comment, and neither company has issued a press release on the situation.
One other thing, if the consensus result in solid tumors is that there are poor or no results, it would be a bonfide reason for the sell off.
There is also end of the year selling for taxes that seems to happen this time of year. A possible rotation out of biotech. Not too long ago, cancer immunotherapy stocks were for the most part approaching overbought. it could be sell on the news, most news is out for awhile. Numerous parameters are always present that can over rule the logical direction of a stock.
They brought it down before ASH. It certainly is less than a sure thing, but it more likely to go up if brought down.
Dude read some of the threads. I already posted twice saying that it was true that BXLTA was being pursued by SHPG and a mea culpa of sorts. Glad you're the super nova enlightening us all a day late. I even posited that the thread mentioning the piper jaffrey conference might have had something to do with the bump yesterday.
When we see the volume pick up or a price over 40 then we'll know something serious is about to happen. Until then the news article doesn't appear to be announcing anything the investing community didn't already know. So it was likely still a news release to get the retailer's money.
Anyway since BXLTA will see growth and it is being pursued by SHPG it seems like a no brainer.
SInce you're so studious and do so much research, you must have figured out the takeout value. Don't be a dope share it with us.
It's the opposite of what the retailer expects isn't it? They make their most money that way. Could be second leg down of biotech rout. Economy crash coming. I loaded up so not a good sign.
gnoring hides all Finance Message Boards posts made by a user.
Ignoring a user - while viewing a Message Boards post, click Flag | Ignore User.
Unignoring a user - on an ignored Message Boards post, click Flag | UnIgnore User.
Note - Once you have 100 users in your ignore list, you won't be able to ignore more users. You'll know if you reach the limit because you'll receive this message: "Error: Your ignore list is full (maximum 100)"
Anybody want to lay out a thesis on the price of the takeout? I'll go with 300 per share so people can claim to be conservative when they say 70 to 100 per share.
it would be nice to see 48-50, but I can't formulate a valuation.
Very possibly the thread above alerting retailers like myself that they are definetely pursuing BXLT:
Shire Presentation at Piper Jaffray Conference
Dec 1, 2015 4:02 PM
There is no doubt that Shire is trying to acquire BXLT. They said so in the presentation. Doesn't look like I'm going to get shares at 33.